ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1706

Multi-omic Study in Patients with SITRAME Syndrome
Abstract Number: 1707

TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Abstract Number: 1708

Unveiling the Uterine-Joint Axis: Dysbiosis and Subclinical Uterine Inflammation in Female Axial Spondyloarthritis Pathogenesis
Abstract Number: 1709

Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis
Abstract Number: 1710

Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA
Abstract Number: 1711

Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
Abstract Number: 1712

Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment
Abstract Number: 1713

Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Propensity Score-Matched Study Using National Veterans Affairs Data
Abstract Number: 1714

Avoidable Hospitalizations by Persons with Rheumatoid Arthritis: A Population-Based Study Using Administrative Data
Abstract Number: 1715

Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
Abstract Number: 1716

Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Abstract Number: 1717

Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Abstract Number: 1718

Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Abstract Number: 1719

Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Abstract Number: 1720

Herpes Zoster Risk Following Initiation of Immunosuppressive Therapy Among Adults with Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].